Patients with familial hypercholesterolaemia (FH) have an elevated cardiovascular (CV) risk. The objective of this analysis was to adjust CV risk equations derived in non-FH populations with hyperlipidaemia to predict CV risk in FH patients, and then to use these adjusted CV risk equations in a decision analytic model in order to predict lifetime CV risk in FH patients. 
Introduction
Familial hypercholesterolaemia (FH) is a genetic disorder characterized by autosomal inheritance in genes related to low-density lipoprotein cholesterol (LDL-C) metabolism, which results in lifelong elevation of LDL-C levels. 1 FH is an under-recognized and undertreated cause of cardiovascular disease (CVD). These patients are usually identified through the development of end-organ damage, the serendipitous performance of an LDL-C measurement, or an active screening program because of a family association or a general population-level program. 2 When untreated, most patients with FH tend to die of myocardial infarction (MI) or other major CV events. 1 Early diagnosis and the prevention of primary CV events in FH patients through treatment of LDL-C levels with lipid modifying therapy (LMT) and modification of other risk factors is an effective disease management strategy. 3 The effectiveness of primary prevention has Cardiology. 4 Screening uses clinical criteria for FH for practical reasons and no genetic mutations are identified in many patients who have a clinical phenotype of FH. 5 The effectiveness of screening programs and the availability of proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, which can lower LDL-C levels in FH patients, has created the need to predict the magnitude of CV risk over time in order to estimate the costeffectiveness of these programs and therapies. Predicting the magnitude of CV risk in FH patients over time requires accounting for differences in population characteristics. Validated decision analytic models are good tools within which CV risk equations can be operationalized. Estimating the increase in CV risk resulting from FH is complicated by the difficulty in establishing inception cohorts of risk, the relative rarity of the condition (estimated frequency of 1:500 2 ), the presence of multiple competing risk factors involved and the impact of the intervention in modifying the natural history of FH and CV risk in this population. Commonly quoted CV risk estimates are derived from registries. Case ascertainment with registries is, however, likely to be biased towards patients experiencing symptoms and CV events. CV risk in FH patients is life-long; however, inception cohorts to estimate increased CV risk are derived from patients at varying stages of their lives, creating biased cohorts based on the recruitment strategy deployed. When FH is identified, modification of risk factors, particularly LDL-C treatment, will reduce CV risk.
Comparison of populations will likely be contaminated by unidentified FH patients, leading to an overestimation of CV risk in the comparison group.
Prevalence of risk factors such as smoking, obesity, hypertension, as well as their management and impact, will also likely differ between FH and the non-FH population, adding further complexity to calculating the absolute CV risk due to FH. 6, 7 CV risk equations predicting risk in primary 8 and secondary 9 prevention settings have been validated for the non-FH population. The genetic mutation leading to FH is present at birth which results in life-long elevated LDL-C levels with no symptom presentation until the occurrence of end-organ damage. 6 CV risk equations in non-FH population are therefore likely to underestimate the risk in FH patients at the same level of LDL-C elevation, with prolonged increases in LDL-C likely leading to more severe atherosclerotic vessel narrowing. 6 Cardiovascular risk and its consequences are an abstract concept when an individual is currently asymptomatic and ultimately, even when a particular risk level is calculated and communicated, the clinical decision of whether to intervene is up to individual physicians and patients. The challenge is to provide patients with the information about their CV risk, as well as some context for that risk and outcomes, to allow the patient to make an informed personal decision. Decision analysis involves a systematic approach to decision-making under uncertainty. A decision analytic model uses mathematical relationships to define the possible consequences from a set of alternative options being evaluated. Decision analysis has been used in health care evaluation, informing clinical decisions at population and individual levels, and economic evaluation. 10 In this study, CV risk equations derived in non-FH populations were first adjusted by published estimates of the increase in CV risk experienced by FH patients and then included in a decision analytic model which predicts CV risk in FH patients over lifetime.
Methods
Published CV risk equations, derived in non-FH populations from the Framingham Heart Study, for patients without existing CVD, 8 and the REduction of Atherothrombosis for Continued Health (REACH) registry, 9 for patients with existing CVD, were used to predict baseline CV risks, which were then converted to rates (see Supplementary material online, File 1 for information about the two risk equations above). Due to long-term exposure to higher levels of LDL-C, FH patients have an elevated baseline CV risk. 1 To determine the level of increased CV risk, a literature review of publications reporting CV risk in FH patients was conducted.
Literature review
A previously described systematic literature review identified 712 publications potentially containing estimates of CV risk in FH. 11 The literature review identified all papers containing estimates of CV risk in FH through multiple search pathways, including a PubMed search, search of FH registries, prior reviews, and references contained within those papers. These 712 publications were reduced to 29 eligible publications based on title and abstract screening. After screening of 29 full-texts, 14 papers were subject to formal bias assessment by two independent reviewers. Of 14 papers that were subject to bias assessment, Benn et al. 12 was identified as having the most credible estimate of CV risk in FH by virtue of exhibiting the least bias based on modified Newcastle-Ottawa criteria. 11 Benn et al. 12 investigated the prevalence and CV risk of FH patients in a population of 69,016 individuals from the Danish general population in the Copenhagen General Population Study. This was the only paper identified to use a general population survey approach, and was the only study to have no source of high-risk bias. From the general population survey data, the probability of patients having FH was determined by applying the Dutch Lipid Clinic Network Criteria. The criteria were modified from the original to only data elements available in the Danish Survey and included family and clinical CVD history, physical examination, and biochemical results (LDL-C) for specifying FH diagnosis. 5 The modified criteria might underestimate the number of definite FH patients which could have an uncertain effect on the CV risk profile of the group. Providing a comparison group internal to the survey, rather than using an external comparison group such as general population, improved the validity of the comparison.
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Adjusted cardiovascular event rates in the familial hypercholesterolaemia population
The odds ratios (ORs) reported by Benn et al. 12 were used to calculate the rate ratio (RR) of CV events in patients with FH vs. non-FH. According to Benn et al., 12 more than half (260/502) of the definite or probable FH patients were untreated. To represent the real world setting, pooling treated and untreated groups was undertaken, accounting for the mix of primary and secondary prevention (patients with a history of CV events) patients as well as different treatment paradigms. The OR was converted to a RR using established methods, 13 which involves:
(1) Computing the crude odds for the reference group (non-FH untreated patients) based on crude event rates; (2) Computing odds for the other groups adjusting the crude odds by the corresponding OR; (3) Converting odds into risk as risk = odds/(1 þ odds); (4) Pooling risks of treated and untreated FH and non-FH patients using a weighted average; (5) Converting pooled risks in FH and non-FH patients to pooled rates (assuming a constant rate over time) as rate = -ln (1 -risk); 
Decision analytic model
A decision analytic model was used to predict lifetime CV risk in FH patients. 14 The model, which incorporates the modified CV risk equations, allows for predictions of risk beyond the time frames considered to estimate the original CV risk equations (10 years for Framingham 2008 8 and 20 months for REACH 2012 9 ). This enables risk to be dependent on previous event history and also accounts for CV and non-CV mortality ( Figure 1) . The model comprises several health states, which include no CVD, established CVD (ECVD), three acute event states (acute coronary syndrome, ischaemic stroke, and heart failure), and three post-acute health states. Additionally, a distinction is made between CV and non-CV death, as FH is assumed to modify fatal CV event rates but not non-CV mortality. The model allows the cohort to experience recurring CV events over the time horizon and keeps track of CV event history, ensuring that the effect of prior CV events on risk is accounted for. 
Characteristics of the familial hypercholesterolaemia population used in the economic model
To illustrate CV risk in FH patients, patient characteristics from the RUTHERFORD-2 clinical trial were used to predict the CV risk ( Table 2) . The RUTHERFORD-2 trial was a multi-national study recruiting a cohort of patients with FH. 15 Patients receiving a stable dose of a statin, with or without other approved LMT for at least 4 weeks before screening, were eligible for inclusion. Cholesterol levels (Total-C and HDL-C) used in the adjusted Framingham 2008 equation were taken from Benn et al.
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( Table 2) . Since elevated LDL-C is the major driver of the increased CV risk in FH patients, adjusting risk predictions while at the same time increasing LDL-C levels might lead to an overestimation of the risk in this population ( Table 2) . 16 The REACH 2012 equation 9 does not include any cholesterol measures as covariates. The number of vascular beds affected and history of atrial fibrillation were assumed from the original REACH 2012 publication 9 due to lack of data. All CV risk factors, other than age, were assumed to be constant over time.
Mortality data
The US life tables were used to estimate non-CVD mortality by age and gender. 17 Cardiovascular disease mortality was estimated using the economic model.
Outcomes
Ten-year and lifetime CV risk [probability of experiencing one or more event, including acute coronary syndrome (ACS), ischaemic stroke (IS), heart failure (HF), and CV mortality] were computed. Lifetime CV event rate (number of events per patient, including ACS, IS, HF, and CV mortality) were also estimated.
Results
The predicted 10-year CV risk (one or more event) from the decision analytic model was 45% in the base case, meaning one out of two FH patients treated with current therapies would experience at least one CV event in the following 10 years. The risk was higher for secondary prevention (61%) than for primary prevention (32%) patients. The risk was also higher for older patients (51% at average age of 56 vs. 39% at average age of 46). The predicted lifetime risk ranged from 86% (primary prevention) to 91% (secondary prevention), meaning FH patients treated with current therapies will almost certainly experience an event in their life. Lifetime risks were similar in the different scenarios, as primary prevention patients will eventually become secondary prevention and the effect of age would be diluted over time ( Table 3) . The predicted lifetime CV event rate was 2.15 (0.79 being fatal events) in the base case, meaning FH patients would experience, on average, two CV events in their life, one of them being fatal. The predicted lifetime rate would be 0.55 (0.23 being fatal events) without considering any FH adjustment on risks. The initial crosssectional RR of 7.1 (95% CI: 5.7-8.7) would therefore convert to FH patients being predicted to have 3.9 times more events over a lifetime horizon than non-FH patients with a similar risk profile. The lifetime RR was lower than the cross-sectional RR due to differences in average survival between FH (18 years) and non-FH (31 years) over lifetime ( Figure 2 ).
Discussion
We have used the least biased assessment of the increased CV risk in FH patients to adjust existing risk equations developed in non-FH patients for primary and secondary CV events. The adjusted equations were included in a decision analytic model allowing for risk prediction over lifetime in FH populations with varying characteristics. We have applied these adjusted CV risk equations to FH patients recruited into a clinical trial and shown their CV risk to be within the definition of high and very high risk according to European clinical guidelines. 18 Decision analytic models are an important tool in guiding therapeutic choice where multiple therapies exist for the treatment of a condition and a key component of health technology assessment filings. 10 Models have the ability to allow for the application to different populations based on characteristics that affect the risk of disease. Validated equations from Framingham 2008 8 and REACH 2012 9 studies have been used in determining the CV risk of primary and secondary events adjusting for population risk factors. These equations were built on long-term non-FH population studies or with large international study populations, an impossible endeavor for FH where the condition is relatively rare and risk reduction strategies are employed when a patient is identified. To our knowledge, however, diagnosis of FH was not explicitly a reason for exclusion in either of the CV risk equation studies. Adjustment of existing CV risk equations to represent FH patients based on estimates of the increased CV risk of FH compared with non-FH would represent a reasonable alternative. direct association with greater value in risk prevention if the risk of adverse outcomes is higher. Even before symptoms of CVD occur, some patients with FH show signs of increased LDL-C, such as tissue xanthomas and corneal arcus, but the condition is otherwise asymptomatic. 6 Criteria have been established to determine the likelihood of a patient having FH and specific genetic testing is available for a number of associated alleles that have facilitated the development of targeted population screening programs and registries for FH. 2 These features with relatively low prevalence and the silent symptomatic nature have complicated the investigation of the epidemiology of FH and have made the specific quantification of CV risk difficult. 1 The use of registry data 19, 20 as a source of CV risk estimates is commonly quoted but challenged by the effects of ascertainment bias and concurrent treatment bias. A population-based investigation, as determined from our review of studies, was identified as the single least biased method for determining increased CV risk in FH. 11 The dramatically increased CV risk at a young age formed the basis of the initial observations in families that led to the subsequent identification of the genetic defects in the LDL-receptor gene. 6 The prior systematic review identified the study by Benn et al. 12 as the only population-based study of CV risk in FH. There are limitations, however, associated with the use of data from this study. The ascertainment of LMT use in the study was through a primary survey questionnaire, which asked for LMT use at that time, but no data are provided as to the use of LMT over time. The study examined the rate of a genetic disorder within Denmark, which might limit generalizability to other countries. Cardiovascular risk in FH is due almost solely to the fact of increased LDL-C, which is exacerbated in FH by the prolonged lifetime nature of the increase in LDL-C. 6, 7 Patients with FH will certainly have an increased risk of CVD compared with non-familial forms of increased LDL-C at the same level of elevated LDL-C because of the highly prolonged exposure of the vasculature to the cholesterol levels. Simply applying non-FH CV risk equations to patients with FH would vastly underestimate the FH risk seen in clinical practice, where patients present with a higher rate of CVD at a younger age. The predicted CV risk in FH computed directly from the adjusted risk equations incorporated into a decision analytic model show a high absolute CV risk in FH, where there is a RR of CV events of 3.9 over lifetime vs. non-FH patients. On average, a patient with FH will likely experience two CV events and almost a 100% lifetime risk of at least one CV event. While these risk levels are impressive, the communication of a particular risk level in isolation is an abstract concept to a patient who is currently asymptomatic. Common exposures and their associated consequences and risk levels that have entered the public discourse through patient educational campaigns (e.g. smoking and lung cancer) or celebrities creating a public discussion on a particular risk type (e.g. BRCA mutations and breast/ovarian cancer) can create context for the risk levels described here. In context, the increased CV risk levels associated with FH can be compared with other types of clinical risk where clinical decisions are made in managing patient care: the relative risk of lung cancer (2-25 times) in smokers, 21 and the relative risk of breast (4 times) and ovarian cancer (15-30 times) in patients with BRCA1/2 mutations.
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The adjusted CV risk equations may now be used in health policy decision-making for calculating the potential value of screening programs and for the use of interventions in FH. There is ample evidence as to the effectiveness of CV risk reduction in FH and, with these adjusted equations, calculation of cost-effectiveness can now be made with greater confidence. Validation of these new models will come from further long-term observation of actual event rates in FH patients compared with predicted rates.
Conclusion
We predicted lifetime CV risk in FH patients through the adjustment of existing CV risk equations and the use of a decision analytic model. The absolute CV risk due to FH is very high and represents an unmet medical need for patients. Similar to cancer, increased efforts for better diagnosis and management of FH should be employed to improve patient outcomes.
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